Evelo Biosciences (EVLO) Stock Price, News & Analysis

Company Overview

Evelo Biosciences, Inc. was a clinical-stage biotechnology company focused on developing orally administered medicines designed to modulate the immune system through the small intestinal axis. The company’s approach centered on “monoclonal microbials,” which are defined strains of bacteria intended to produce targeted effects on immune and inflammatory pathways.

Evelo’s development programs included EDP1815, an investigational treatment studied in inflammatory diseases such as atopic dermatitis and psoriasis, and EDP2939, an investigational program intended to address immune-mediated conditions. The company’s research was based on the potential for signals originating in the small intestine to influence systemic immune responses without broadly suppressing the immune system.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Evelo conducted clinical development activities in the United States and other markets through research and trial collaborations. The company later announced plans to wind down operations and pursue alternatives for its assets after facing financial and development challenges. Accordingly, Evelo is best described as a former biotechnology company whose principal programs and platform were focused on immune-modulating therapies.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 25 shs
• Average Volume: 7,613 shs
• Market Capitalization: $2 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/13/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:EVLO
• CIK: 1694665
• Web: www.evelobio.com
• Phone: (617) 577-0300
• Fax: N/A
• Employees: 120
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,840,000
• Free Float: 18,789,000
• Market Cap: $2 thousand
• Optionable: No Data
• Beta: 1.34